<DOC>
	<DOCNO>NCT00089167</DOCNO>
	<brief_summary>RATIONALE : Drugs melphalan , thalidomide , dexamethasone may effective treat patient primary systemic amyloidosis . PURPOSE : This phase II trial study well give melphalan together thalidomide dexamethasone work treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>Melphalan , Thalidomide , Dexamethasone Treating Patients With Newly Diagnosed , Previously Untreated Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year overall progression-free survival patient newly diagnose , previously untreated primary systemic ( AL ) amyloidosis treat risk-adapted melphalan follow thalidomide dexamethasone . Secondary - Determine plasma cell disease response patient 3 , 12 , 24 month treatment regimen . - Determine amyloid-related disease response patient 12 24 month treatment regimen . - Determine prognostic significance immunoglobulin light-chain variable-region germline gene expression AL plasma cell clone patient treat regimen . - Determine whether molecular minimal residual disease 12 24 month patient achieve complete hematologic response treatment regimen . OUTLINE : Patients stratify accord extent amyloid-related disease ( low-risk v high-risk ) . - High-risk disease : Patients receive 2 course low-dose melphalan IV , dexamethasone , filgrastim ( G-CSF ) . After 3 month , patient receive thalidomide dexamethasone plasma cell disease persist . - Low-risk disease : Patients receive 1 course high-dose melphalan IV G-CSF . Patients receive thalidomide dexamethasone high-risk disease regimen . Patients follow 3 , 12 , 24 month . PROJECTED ACCRUAL : A total 82 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary systemic ( AL ) amyloidosis within past 12 month High lowrisk disease , determine extent systemic organ involvement disease patient age PATIENT CHARACTERISTICS : Age 18 Performance status SWOG 03 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No New York Heart Association class III IV congestive heart failure No restrictive cardiomyopathy require oxygen No myocardial infarction within past 6 month No symptomatic cardiac arrhythmia within past 60 day Other No active malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy AL amyloidosis Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior concurrent therapy AL amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>